Monte Rosa Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Monte Rosa Therapeutics Inc 's ROA in the second quarter of 2026?
Monte Rosa Therapeutics Inc recorded a cumulative net loss of $-161 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -22.49%.

However, within the Healthcare sector 406 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3563, from total ROA ranking in the first quarter of 2026 at 3715.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	244.26 %	89.01 %	3.16 %	46.45 %	4.21 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-161	-130	-39	21	24
Return On Assets (TTM)	-22.49 %	-26.04 %	-9.36 %	5.12 %	6.48 %
GLUE's Total Ranking	# 3563	# 3715	# 1177	# 965	# 1907
Total Assets (TTM) in million	1,224	736	449	456	356
Seq. Total Assets Change	66.19 %	64.14 %	-1.7 %	28.38 %	-8.75 %
Seq. Net Income Change	-	-	-	-	-

GLUE's 5 Years Annual ROA >> Back to GLUE Management Effectiveness >> Compare GLUE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 42
Sector	# 407
Overall	# 3563

Return On Assets Statistics
High	Average	Low
6.42 %	-26.43 %	-49.14 %
(Jun 30 2025)		(Mar 31 2024)

Financial Statements
Monte Rosa Therapeutics Inc 's Assets	$ 1,224 million	GLUE's Balance sheet
Monte Rosa Therapeutics Inc 's Income	$ -43 million	Quarterly GLUE's Income Statement
GLUE's Income by Division		See GLUE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	3.16 %	44.97 %	-11.49 %	-6.1 %	-
Total Assets in million	449	435	300	339	361
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-39	-73	-135	-109	-74
Annual Return On Assets	-8.61 %	-16.72 %	-45.12 %	-32.01 %	-20.49 %

GLUE's 5 Years Annual ROA >> Back to GLUE Management Effectiveness >> Compare GLUE ROA to its Competitors

More Return On Assets Ratios
GLUE's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GLUE's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GLUE's Competitors
Subscribers only: Roa for Monte Rosa Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for GLUE's Customers

You may also want to know
GLUE's Roi	GLUE's Inventory Turnover Ratio	GLUE's Growth Rates	GLUE's Dividend Comparisons
	GLUE's Profitability Ratios	GLUE's Asset Turnover Ratio	GLUE's Dividend Growth
GLUE's Roe	GLUE's Valuation Ratios	GLUE's Financial Strength Ratios	GLUE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:53:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.